Primary Squamous Cell Carcinoma of the Male Proximal Urethra: Outcomes from a Single Centre.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
01 2021
Historique:
received: 04 09 2018
revised: 05 02 2019
accepted: 25 02 2019
pubmed: 12 3 2019
medline: 26 3 2022
entrez: 12 3 2019
Statut: ppublish

Résumé

Primary squamous cell carcinoma (SCC) of the male proximal urethra is an aggressive and rare urogenital malignancy. To review the surgical management and outcomes for male proximal urethral SCCs within a single centre and to suggest an algorithm for the surgical management of these rare tumours. This was a retrospective study of patients undergoing surgery for male proximal urethral SCC within a single tertiary academic centre managing rare genital tumours. Ten patients with a histological diagnosis of proximal urethral SCC were identified from an institutional database over a period of 10 yr with a median follow-up of 22.5 mo (standard deviation±25.77 mo). Pathological staging, surgical treatment, and neoadjuvant and adjuvant treatment were recorded. Complications according to the Clavien-Dindo classification and overall survival rates were recorded. Kaplan-Meier curves were used for overall survival. A total of 10 patients were identified of whom eight underwent panurethrectomy and radical prostatectomy. Radical inguinal lymphadenectomy was performed in five patients, which confirmed bilateral metastatic disease. Perioperative complications were reported in six patients (Clavien I and II). Within 6 mo of surgery, 90% of patients developed distant metastatic disease. Nine patients died of urethra cancer during the follow-up. One patient is still on follow-up. The median overall follow-up was 13.92 mo (range: 5-91 mo). At 5 yr, cancer-specific/overall survival was 10%. A limitation of this study is the retrospective design, which is unavoidable for such a rare disease. Radical surgery allows local disease control, but despite neo/adjuvant treatment, proximal urethral SCC is associated with poor survival outcomes and progression to distant metastatic disease within 6 mo. Proximal urethral squamous cell carcinoma is a rare cancer in men which is often detected late. Patients often present with problems such as voiding, urethral bleeding, or a palpable mass. Aggressive surgery allows local control, but despite this the overall survival is poor. Adjuvant and neoadjuvant radiochemotherapy can improve survival. Multicentric randomised trials are needed to identify the correct treatment modality.

Sections du résumé

BACKGROUND
Primary squamous cell carcinoma (SCC) of the male proximal urethra is an aggressive and rare urogenital malignancy.
OBJECTIVE
To review the surgical management and outcomes for male proximal urethral SCCs within a single centre and to suggest an algorithm for the surgical management of these rare tumours.
DESIGN, SETTING, AND PARTICIPANTS
This was a retrospective study of patients undergoing surgery for male proximal urethral SCC within a single tertiary academic centre managing rare genital tumours. Ten patients with a histological diagnosis of proximal urethral SCC were identified from an institutional database over a period of 10 yr with a median follow-up of 22.5 mo (standard deviation±25.77 mo).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Pathological staging, surgical treatment, and neoadjuvant and adjuvant treatment were recorded. Complications according to the Clavien-Dindo classification and overall survival rates were recorded. Kaplan-Meier curves were used for overall survival.
RESULTS AND LIMITATIONS
A total of 10 patients were identified of whom eight underwent panurethrectomy and radical prostatectomy. Radical inguinal lymphadenectomy was performed in five patients, which confirmed bilateral metastatic disease. Perioperative complications were reported in six patients (Clavien I and II). Within 6 mo of surgery, 90% of patients developed distant metastatic disease. Nine patients died of urethra cancer during the follow-up. One patient is still on follow-up. The median overall follow-up was 13.92 mo (range: 5-91 mo). At 5 yr, cancer-specific/overall survival was 10%. A limitation of this study is the retrospective design, which is unavoidable for such a rare disease.
CONCLUSIONS
Radical surgery allows local disease control, but despite neo/adjuvant treatment, proximal urethral SCC is associated with poor survival outcomes and progression to distant metastatic disease within 6 mo.
PATIENT SUMMARY
Proximal urethral squamous cell carcinoma is a rare cancer in men which is often detected late. Patients often present with problems such as voiding, urethral bleeding, or a palpable mass. Aggressive surgery allows local control, but despite this the overall survival is poor. Adjuvant and neoadjuvant radiochemotherapy can improve survival. Multicentric randomised trials are needed to identify the correct treatment modality.

Identifiants

pubmed: 30853605
pii: S2405-4569(19)30051-3
doi: 10.1016/j.euf.2019.02.016
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

163-169

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Fabio Castiglione (F)

Department of Urology, University College London Hospital, London, UK; NIHR Biomedical Research Centre, University College London Hospital, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.

Hussain M Alnajjar (HM)

Department of Urology, University College London Hospital, London, UK.

Michelle Christodoulidou (M)

Department of Urology, University College London Hospital, London, UK.

Maarten Albersen (M)

Department of Urology, University College London Hospital, London, UK.

Arie Parnham (A)

Department of Urology, University College London Hospital, London, UK.

Alex Freeman (A)

Department of Pathology, University College London Hospital, London, UK.

Charles Jameson (C)

Department of Pathology, University College London Hospital, London, UK.

Anita Mitra (A)

Department of Oncology, University College London Hospital, London, UK.

Raj Nigam (R)

Department of Urology, University College London Hospital, London, UK.

Peter Malone (P)

Department of Urology, University College London Hospital, London, UK.

Asif Muneer (A)

Department of Urology, University College London Hospital, London, UK; NIHR Biomedical Research Centre, University College London Hospital, London, UK; Division of Surgery and Interventional Science, University College London, London, UK. Electronic address: asif.muneer@uclh.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH